Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1Neuroblastoma 1

Interventions

Isotretinoin 3imetelstat 2Peripheral Blood Stem Cell Transplantation 2Cyclophosphamide 2thymoglobulin 1pazopanib 1naxitamab 1lorukafusp alfa 1liposomal doxorubicin 1keyhole-limpet hemocyanin 1fludarabine phosphate 1fludarabine 1defibrotide 1arginyllysine 1Whole-Body Irradiation 1Whole Body Imaging 1Vincristine 1Vaccines 1Tretinoin 1Topotecan 1Thiotepa 1Therapeutics 1Temozolomide 1Tacrolimus 1Stem Cell Transplantation 1Spermine Synthase 1Specimen Handling 1Radiotherapy 1Radiation 1Pentetic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Neuroblastoma × 3-fluorobenzylguanidine × Clear all
NCT06233903 2025-01-21

18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System

Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)

Phase 2 Withdrawn
CNSEndocrine

Neuroblastoma, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡